Pilot Study of the Effect of MN-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin

Type 2 Diabetes Clinical Trial

Official title:

A Pilot Study of the Effect of NM-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin in Patients With Metformin Intolerance

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01866462
• Other study ID #: ProCo Metformin
• Status: Completed
• Phase: Phase 0
• First received: May 28, 2013
• Last updated: July 23, 2014
• Start date: May 2013
• Est. completion date: July 2014

Study information

• Verified date: July 2014
• Source: NuMe Health
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to determine if NM504 will prevent GI side effects that are associated with using metformin for the treatment of diabetes.

Description:

Only subjects with known intolerance to metformin will be recruited and enrolled in this study. When a participant qualifies, after signing the consent, they will be asked to complete a questionnaire about medical history which will be reviewed with the coordinator. Their height, weight, and blood pressure will be measured, and their medications will be reviewed. They will be taught how to measure their fasting blood glucose by a finger stick. They will be given metformin and asked to take a 500mg tablet twice day before breakfast and dinner starting the next day with breakfast. They will be given doses of NM504 or a placebo in a pouch to be mixed with 6 ounces of water before breakfast and dinner as a smoothie drink starting before breakfast the next day. Before consuming the first smoothie each day and before eating any food each day they will be asked to record their fasting finger stick blood glucose and complete the questionnaire about their bowel habits. The study takes place in two-week segments with a two week washout in between. They will receive metformin in both periods, but they will receive NM504 during one 2-week segment and a placebo smoothie during the other two-week segment. Five subjects will receive NM504 and 5 subjects will be assigned placebo during the initial 2 weeks. The treatment sequence will be randomly assigned. After the 2 week washout period the subjects will cross over to either placebo or NM504.

Phone Visit 1: week 1 subjects will receive a call from the coordinator to see how they are tolerating the metformin and the smoothies. An increase in metformin dose to 500mg 3 times a day may or may not happen.

Clinic Visit 2: week 2, Subjects will bring bottle of metformin and empty packages of smoothie powder to the visit along with logs of their daily fasting finger stick blood glucose and their daily bowel questionnaires. Their body weight weight will be measured.

Clinic Visit 3: week 4, subjects will be asked about their metformin tolerance and body weight will be measured. They will be given metformin and asked to take a 500 mg pill twice a day before breakfast and dinner starting the next day before breakfast. Before consuming the first smoothie each day, and before eating any food each day, subjects will be asked to record a fasting finger stick blood glucose and complete the questionnaire about bowel habits.

Phone Visit 2: week 5 subjects will be asked about their tolerance to metformin and the smoothies. They may or may not be asked to increase their 500mg dose of metformin from 2 times a day to 3 times a day.

Clinic Visit 4: week 6, Subjects will bring the bottle of metformin and the empty packages of the smoothie powder to the visit along with the logs of daily fasting finger stick blood glucose and daily bowel questionnaires. Their body weight will be measured at the end of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: July 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Male or a female with type 2 diabetes

• Known tolerance to metformin

• 18 years of age or older

• Body mass index that is not less than 20 kg/m2

Exclusion Criteria:

• Not pregnant or breast feeding a baby.

• Not taking chronic medication that has not had a stable dose for 1 month or longer.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Type 2 Diabetes

Intervention

Other:
• NM504
NM504 is a medical food designed to shift the dysbiota reported in type 2 diabetes. The placebo is carboxymethylcellulose prepared to look, taste and mix like NM504.

Locations

Country	Name	City	State
United States	Pennington Biomedical Research Center	Baton Rouge	Louisiana

Sponsors (2)

Lead Sponsor	Collaborator
NuMe Health	Pennington Biomedical Research Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Metformin Tolerance	Fecal frequency, fecal consistency, fecal score and incidence of diarrhea will be assessed using the validated King's Stool Chart.	6 Weeks	Yes
Secondary	Fasting Blood Glucose	Fasting blood glucose will be measured by finger stick daily.	6 weeks	No
Secondary	GI Symptoms	Other possible GI symptoms such as sensations of bloating and flatulence will be measured with a questionnaire adapted from the validated Irritable Bowel Syndrome Global Improvement Scale.	6 weeks	Yes
Secondary	GI Stool Profile	Stool will be collected at baseline, after the initial 2 week treatment, at the end of the washout period, and at the completion of the study. The complete stool GI function profile assessed by Genova Diagnostics will be performed.	6 weeks	No
Secondary	Weight Loss	Body weight will be measured at each clinic visit.	6 weeks	No